Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours
- PMID: 16050909
- DOI: 10.1111/j.1439-0442.2005.00726.x
Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours
Abstract
The goal of this study was to determine the significance of tumour depth, tumour location and multiple synchronous tumour masses for the prognostic evaluation of canine cutaneous mast cell tumours (MCTs). The study population consisted of 100 formalin-fixed, paraffin-embedded cutaneous MCTs that had been surgically removed from 100 dogs and submitted to the Diagnostic Center of Population and Animal Health at Michigan State University between 1998 and 2001. None of the dogs had received chemotherapy or radiation therapy. For each case the following data were obtained from the referring veterinarians: sex, breed, weight, age at diagnosis, diagnostics performed, adjunct medications given at the time of surgery, tumour location, number of tumour masses, tumour recurrence (development of MCTs at the surgical site), development of additional MCTs at distant sites (outside the surgical margins), tumour duration before removal, survival time and cause of death, if applicable. Tumour depth was determined through microscopic evaluation of 5 microm sections stained with haematoxylin and eosin. Based on univariable and multivariable survival analysis, dogs with multiple synchronous cutaneous MCTs at the time of diagnosis have a worse prognosis compared with dogs with single tumours. Additional treatment beyond surgical excision alone should be considered for these animals. Older dogs and Boxers with cutaneous MCTs were at higher risk to develop additional MCTs at distant sites (outside the surgical margins), and older and male dogs with cutaneous MCTs had significantly shorter survival times. Univariable analysis also determined that dogs with cutaneous MCTs located on the head and neck had an increased risk of additional MCT development at distant sites and that sterilized dogs with cutaneous MCTs had shorter survival times. However, these findings were not confirmed by multivariable analysis. Tumour depth was of no prognostic significance for dogs with cutaneous MCTs.
Similar articles
-
Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.J Am Vet Med Assoc. 2006 Jan 15;228(2):210-5. doi: 10.2460/javma.228.2.210. J Am Vet Med Assoc. 2006. PMID: 16426187
-
Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).J Am Vet Med Assoc. 2006 Jan 1;228(1):91-5. doi: 10.2460/javma.228.1.91. J Am Vet Med Assoc. 2006. PMID: 16426175
-
Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision.J Am Vet Med Assoc. 2012 May 15;240(10):1181-7. doi: 10.2460/javma.240.10.1181. J Am Vet Med Assoc. 2012. PMID: 22559107
-
Principles of treatment for mast cell tumors.Clin Tech Small Anim Pract. 2003 May;18(2):103-6. doi: 10.1053/svms.2003.36624. Clin Tech Small Anim Pract. 2003. PMID: 12831070 Review.
-
Advances in the diagnosis and management of cutaneous mast cell tumours in dogs.J Small Anim Pract. 2007 Aug;48(8):424-31. doi: 10.1111/j.1748-5827.2007.00366.x. Epub 2007 Jun 9. J Small Anim Pract. 2007. PMID: 17559522 Review.
Cited by
-
Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.Cells. 2022 Feb 10;11(4):618. doi: 10.3390/cells11040618. Cells. 2022. PMID: 35203268 Free PMC article. Review.
-
RNAScope in situ Hybridization as a Novel Technique for the Assessment of c-KIT mRNA Expression in Canine Mast Cell Tumor.Front Vet Sci. 2021 Feb 16;8:591961. doi: 10.3389/fvets.2021.591961. eCollection 2021. Front Vet Sci. 2021. PMID: 33665215 Free PMC article.
-
Preliminary Assessment of Tumor-Associated Tissue Eosinophilia (TATE) in Canine Mast Cell Tumors: Prevalence and Prognostic Relevance and Its Association with Neoangiogenesis.Animals (Basel). 2023 Jan 13;13(2):283. doi: 10.3390/ani13020283. Animals (Basel). 2023. PMID: 36670824 Free PMC article.
-
Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).Vet Comp Oncol. 2015 Sep;13(3):267-80. doi: 10.1111/vco.12042. Epub 2013 May 31. Vet Comp Oncol. 2015. PMID: 23721492 Free PMC article.
-
Histopathological features of subcutaneous and cutaneous mast cell tumors in dogs.Acta Vet Scand. 2024 Oct 1;66(1):53. doi: 10.1186/s13028-024-00775-5. Acta Vet Scand. 2024. PMID: 39354622 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical